CN102603816A - 2-fluoro-18F-2-deoxy-beta-D-glucose (FED) kit and preparation method of reagent of same - Google Patents
2-fluoro-18F-2-deoxy-beta-D-glucose (FED) kit and preparation method of reagent of same Download PDFInfo
- Publication number
- CN102603816A CN102603816A CN2012100381432A CN201210038143A CN102603816A CN 102603816 A CN102603816 A CN 102603816A CN 2012100381432 A CN2012100381432 A CN 2012100381432A CN 201210038143 A CN201210038143 A CN 201210038143A CN 102603816 A CN102603816 A CN 102603816A
- Authority
- CN
- China
- Prior art keywords
- packaged
- container
- reagent
- volume
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a 2-fluoro-18F-2-deoxy-beta-D-glucose (FED) kit and a preparation method of a reagent of the same and belongs to the technical field of kits. The kit comprises a kit body and is characterized in that a first container containing H2<18>O, a second container containing mannose triflate, a third container containing a phase transfer catalyst, a fourth container containing acetonitrile, a fifth container containing ethanol, a sixth container containing a hydrolysis reagent, a packaged purification column and a vacuum flask are arranged in the kit body. According to the invention, the synthesis of FDG can be directly finished without independently preparing other reagents for synthesizing FDG in the existing technology, thereby bringing convenience to the PET-CT (Positron Emission Tomography-Computed Tomography) application departments; and the method can be used for accurately measuring the reagent and is favorable for guaranteeing the using effect.
Description
Technical field
The invention belongs to the test kit technical field, be specifically related to a kind of 2-fluoro-18 generation-2 deoxidation-β-D-glucose kit, and relate to the compound method of the reagent in this test kit
Background technology
aforesaid 2-fluoro-18 generation-2 deoxidation-β-D-glucose (being called for short FDG) are generally used for Positron Emission Computed Tomography, and (position emissron tomography is called for short: detection reagent PET).PET can reflect the picture reproducer of gene, molecule, metabolism and the functional status of pathology.It is to utilize body metabolism thing such as positron radionuclide labelled glucose as developer, through focus the picked-up of developer is reflected its metabotic change, thereby is the clinical biological metabolism information that disease is provided.Be the new milestone of current life science, medical image technical development, CT (Computed Tomography) is the x-ray tomography imaging technique that people are familiar with.Can clearly obtain the anatomical information of pathology; But only depend on the constructional feature limitation that diagnosed the illness; The character of some pathology has or not recurrence such as very pernicious, the operation back tumour of tumour, and CT all is difficult to make judgement accurately, can not reflect the physiological metabolism state of disease exactly.PET-CT is incorporated into PET and CT on the instrument; Form a complete imaging system, be known as PET-CT system (integrated PET-CT system), patient when inspection through body scan fast; Can obtain CT anatomic image and PET functional metabolism image simultaneously; Two kinds of images mutual supplement with each other's advantages make the doctor when understanding biological metabolism information, obtain to dissect accurately the location, thereby disease are made judgement comprehensively and accurately.
utilize part and the water etc. of compound or metabolism substrate such as glucose, lipid acid, amino acid, the acceptor of isotope labeling such as some physiological requirements of positron emitter; After introducing in the body, use the positron scanning machine and chemical image in the body that obtains.It is clinically paid attention to function and the distribution and receiving that it can show metabolic activity and the acceptor of internal organs or tissue widely, also is referred to as " the biochemical video picture of live body ".We can say; The appearance of PET makes the medical image technology reach a brand-new level; Make physiology, biochemical change non-invasive, dynamic, quantitative evaluation biological tissue or organ metabolic activity in cells under physiological status and in the lysis; The information that obtains molecular level becomes possibility, this be at present other any methods can't realize.Therefore in developed country, PET is widely used in clinical, has become the effective means of the guiding treatment of this three big human lifes of threat medical diagnosis on disease of tumour, coronary heart disease and encephalopathy.The most frequently used PET developer is the FDG (18F-FDG fluoridizes deoxyglucose) of 18F mark at present, is a kind of analogue of glucose.
are present; PET uses department and particularly prepares or claim that the method for autonomous preparation prepares FDG in the medical department scene of mostly adopting; The clean requirement that the shortcoming of on-site prepn FDG is that preparation time is tediously long, productive rate and quality accuracy unstable, proportioning are difficult to hold and prepare environment can't ensure; Thereby influence imaging results, and then influence is to the diagnosis effect of disease.Therefore, a kind ofly can synthesize the various compositions that FDG uses and gather in test kit together if having, just so aforesaid shortcoming can be eliminated according to correct proportioning.The applicant has made good try for this reason, and the technical scheme that will introduce below produces under this background
Summary of the invention
task of the present invention is to provide a kind of 2-fluoro-18 generation-2 deoxidation-β-D-glucose kit, in this test kit, is equipped with each composition that is used for synthetic FDG that obtains through accurate and reasonable proportioning to use to PET-CT application department and provides convenience.
another task of the present invention is to provide the compound method of the reagent in a kind of 2-fluoro-18 generation-2 deoxidation-β-D-glucose kit, and this method has the reagent accurate measurement and uses the imaging effect that ensures the PET-CT system.
task of the present invention is accomplished like this; A kind of 2-fluoro-18 generation-2 deoxidation-β-D-glucose kit; Comprise a test kit box body, be characterised in that: in described test kit box body, be provided with first container, second container that is packaged with mannose triflate, the 3rd container that is packaged with phase-transfer catalyst, the 4th container that is packaged with acetonitrile that are packaged with oxygen 18 water, be packaged with alcoholic acid the 5th container, be packaged with the 6th container of hydrolysing agent, the purification column and the vacuum vessel of packing.
another task of the present invention is accomplished like this; The compound method of the reagent in a kind of 2-fluoro-18 generation-2 deoxidation-β-D-glucose kit, this method are that the oxygen 18 water with 1.8-2.2g is packaged in first container that volume is 10ml; The mannose triflate of 20-30mg is packaged in second container 3 that volume is 8ml; Phase-transfer catalyst is packaged in the 3rd container that volume is 8ml, wherein: phase-transfer catalyst is the cryptand 222 of 20-25g or the TBAH aqueous solution of 0.6ml 0.15M (0.15M is a volumetric molar concentration); The acetonitrile of 5-10ml is packaged in the 4th container that volume is 20ml; The ethanol of 10-30ml is packaged in the 5th container that volume is 50ml; Hydrolysing agent is packaged in the 6th container that volume is 8ml, wherein: hydrolysing agent is the sodium hydroxide solution of 1ml 1M (volumetric molar concentration) or the hydrochloric acid soln of 1ml 1M; Purification column is placed plastics tubing; Vacuum tightness is-0.09～-0.1MPa and volume are that the vacuum vessel of 20ml places EPE.
In a concrete embodiment of the present invention, described purification column is made up of Zeo-karb, anion exchange resin, aluminum oxide and macroporous resin and is contained in the described plastics tubing
.
in another concrete embodiment of the present invention, described plastics tubing is a pp pipeline.
technical scheme provided by the invention is owing to be equipped with the various compositions and corresponding instrument that are used to prepare FDG in the test kit box body; Thereby can directly accomplish synthesizing to FDG; And need not to resemble the prior art separately other reagent that preparation separately is used for synthetic FDG, for PET-CT application department provides convenience; The method reagent accurate measurement that provides and help ensureing result of use.
Description of drawings
Fig. 1 is the synoptic diagram of test kit of the present invention.
Embodiment
Embodiment 1:
see also Fig. 1, in the test kit box body 1 that provides, are provided with: be packaged with first container 2 of oxygen 18 water, this first container 2 is the vial of 10ml; Be packaged with second container 3 of 30mg mannose triflate, this second container 3 is the vial of 8ml; The 3rd container 4, the three containers 4 that are packaged with phase-transfer catalyst are the vial of 8ml, and wherein, phase-transfer catalyst is that the mass percent concentration of 0.6ml is the TBAH aqueous solution of 0.15M; The 4th container 5, the four containers 5 that are packaged with the acetonitrile of 10ml are the vial of 20ml; Alcoholic acid the 5th container 6, the five containers 6 that are packaged with 20ml are the vial of 20ml; Be packaged with 1ml's and mass percent concentration is that the 6th container 7, the six containers 7 of 1% hydrochloric acid soln are the vial of 8ml; The purification column 8 of packing; This purification column 8 is made up of anion and cation exchange resin, aluminum oxide and macroporous resin and is contained in material is in the polyacrylic plastics tubing; Wherein, negatively charged ion: positively charged ion: aluminum oxide: the weight ratio of macroporous resin is 4: 0.5～2: 0.5～2: 0.5～2); By EPE packaging and vacuum tightness be-vacuum vessel 9 of 0.09MPa.Wherein: aforesaid vial and purification column 8 are positioned in the EPE, on EPE, reserve the hole in advance,, and then EPE packed in the test kit box body 1 so that vial puts.
Embodiment 2:
only the amount with oxygen 18 water change 2.2g into; Change the amount of mannose triflate into 20mg; Phase-transfer catalyst is used instead the cryptand 222 of 25mg; Change the amount of acetonitrile into 5ml; Change the alcoholic acid amount into 30ml; The vacuum tightness of vacuum vessel 9 is changed into-0.1MPa, and all the other are all with the description to embodiment 1.
Embodiment 3:
Only the amount with oxygen 18 water changes 2g into; Change the amount of mannose triflate into 25mg; Phase-transfer catalyst is used instead the cryptand 222 of 20mg; Change the alcoholic acid amount into 10ml; Use hydrolysing agent instead 1ml and mass percent concentration is 1% sodium hydroxide solution; The vacuum tightness of vacuum vessel 9 is changed into-0.095MPa, and all the other are all with the description to embodiment 1
Claims (4)
1.
a kind of 2-fluoro-18 generation-2 deoxidation-β-D-glucose kit; Comprise a test kit box body (1), it is characterized in that: in described test kit box body (1), be provided with first container (2) that is packaged with oxygen 18 water, second container (3) that is packaged with mannose triflate, the 3rd container (4) that is packaged with phase-transfer catalyst, the 4th container (5) that is packaged with acetonitrile, be packaged with alcoholic acid the 5th container (6), be packaged with hydrolysing agent the 6th container (7), the packing purification column (8) and vacuum vessel (9).
2. the compound method of the reagent in
a kind of 2-fluoro-18 generation-2 deoxidation-β according to claim 1-D-glucose kit is characterized in that this method is that oxygen 18 water with 1.8-2.2g is packaged in first container (2) that volume is 10ml; The mannose triflate of 20-30mg is packaged in second container (3) that volume is 8ml; Phase-transfer catalyst is packaged in the 3rd container (4) that volume is 8ml, wherein: phase-transfer catalyst is the cryptand 222 of 20-25g or the TBAH aqueous solution of 0.6ml 0.15M; The acetonitrile of 5-10ml is packaged in the 4th container (5) that volume is 20ml; The ethanol of 10-30ml is packaged in the 5th container (6) that volume is 50ml; Hydrolysing agent is packaged in the 6th container (7) that volume is 8ml, wherein: hydrolysing agent is the sodium hydroxide solution of 1ml 1M or the hydrochloric acid soln of 1ml 1M; Purification column is placed plastics tubing; Vacuum tightness is-0.09～-0.1MPa and volume are that the vacuum vessel (9) of 20ml places EPE.
3. the compound method of the reagent in
a kind of 2-fluoro-18 generation-2 deoxidation-β according to claim 2-D-glucose kit is characterized in that described purification column is made up of Zeo-karb, anion exchange resin, aluminum oxide and macroporous resin and is contained in the described plastics tubing.
4.
The compound method of the reagent in a kind of 2-fluoro-18 generation-2 deoxidation-β according to claim 3-D-glucose kit is characterized in that described plastics tubing is a pp pipeline
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100381432A CN102603816A (en) | 2012-02-20 | 2012-02-20 | 2-fluoro-18F-2-deoxy-beta-D-glucose (FED) kit and preparation method of reagent of same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100381432A CN102603816A (en) | 2012-02-20 | 2012-02-20 | 2-fluoro-18F-2-deoxy-beta-D-glucose (FED) kit and preparation method of reagent of same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102603816A true CN102603816A (en) | 2012-07-25 |
Family
ID=46521638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100381432A Pending CN102603816A (en) | 2012-02-20 | 2012-02-20 | 2-fluoro-18F-2-deoxy-beta-D-glucose (FED) kit and preparation method of reagent of same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102603816A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109059591A (en) * | 2018-07-19 | 2018-12-21 | 上海四埃美微科技有限公司 | A kind of Synchronous Heating pipe and its preparation method and application |
| CN110352056A (en) * | 2016-12-02 | 2019-10-18 | 俄克拉何马大学董事会 | Imaging agent and application method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102391318A (en) * | 2011-08-22 | 2012-03-28 | 常熟华益化工有限公司 | Fluorine-18 fluorodeoxyglucose (18F-FDG) kit and application thereof in synthesis of positron emission tomography (PET) developer FDG |
-
2012
- 2012-02-20 CN CN2012100381432A patent/CN102603816A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102391318A (en) * | 2011-08-22 | 2012-03-28 | 常熟华益化工有限公司 | Fluorine-18 fluorodeoxyglucose (18F-FDG) kit and application thereof in synthesis of positron emission tomography (PET) developer FDG |
Non-Patent Citations (1)
| Title |
|---|
| 王清等: "利用Siemens Explora FDG4化学合成模块合成18F-FDG的方法及质量控制", 《现代医药卫生》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110352056A (en) * | 2016-12-02 | 2019-10-18 | 俄克拉何马大学董事会 | Imaging agent and application method |
| CN109059591A (en) * | 2018-07-19 | 2018-12-21 | 上海四埃美微科技有限公司 | A kind of Synchronous Heating pipe and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hennrich et al. | [68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging | |
| Jung et al. | Whole-body tracking of single cells via positron emission tomography | |
| Paans et al. | Positron emission tomography: the conceptual idea using a multidisciplinary approach | |
| Collingridge et al. | In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope | |
| US20210220492A1 (en) | 99mTc-LABELED ISONITRILE-CONTAINING GLUCOSE DERIVITIVE AND PREPARATION METHOD AND USE THEREOF | |
| van der Meulen et al. | New radionuclides and technological advances in SPECT and PET scanners | |
| Hugon et al. | [18F] 2-fluoro-2-deoxy-sorbitol PET imaging for quantitative monitoring of enhanced blood-brain barrier permeability induced by focused ultrasound | |
| Boschi et al. | Technetium-99m radiopharmaceuticals for ideal myocardial perfusion imaging: lost and found opportunities | |
| Gower-Fry et al. | Recent advances in the clinical translation of silicon fluoride acceptor (SiFA) 18F-radiopharmaceuticals | |
| Oroujeni et al. | The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR: 2377 Affibody Molecule | |
| TW200826964A (en) | Radioactive diagnostic imaging agent | |
| Fani et al. | Selection of the first 99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation—Preclinical assessment of two optimized candidates | |
| CN102603816A (en) | 2-fluoro-18F-2-deoxy-beta-D-glucose (FED) kit and preparation method of reagent of same | |
| CN102391318B (en) | Fluorine-18 fluorodeoxyglucose (18F-FDG) kit and application thereof in synthesis of positron emission tomography (PET) developer FDG | |
| Stotz et al. | Covalent 18F-radiotracers for SNAPTag: A new toolbox for reporter gene imaging | |
| Nguyen et al. | Recent developments in PET and SPECT radiotracers as radiopharmaceuticals for hypoxia tumors | |
| Csikos et al. | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn] Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model | |
| Kersting et al. | Shining damaged hearts: immunotherapy-related cardiotoxicity in the spotlight of nuclear cardiology | |
| Luo et al. | SPECT imaging with Tc-99m-labeled HYNIC-FAPI-04 to extend the differential time window in evaluating tumor fibrosis | |
| CN105884867B (en) | 18The affinity body class compound and the preparation method and application thereof of F label | |
| Jiang et al. | Radiosynthesis and Bioevaluation of 99mTc-Labeled Isocyanide Ubiquicidin 29-41 Derivatives as Potential Agents for Bacterial Infection Imaging | |
| Vanderheyden | The use of imaging in preclinical drug development | |
| Gerbaudo | A Case-based Approach to PET/CT in Oncology | |
| Wang et al. | Use of Imaging for Preclinical Evaluation | |
| Kim et al. | Synthesis and Evaluation of 99m Tc-Labeled Folate-Tripeptide Conjugate as a Folate Receptor-Targeted Imaging Agent in a Tumor-Bearing Mouse Model |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 215522 fluorine chemical industry park, Changshu Economic Development Zone, Jiangsu Applicant after: Jiangsu Huayi Science & Technology Co., Ltd. Address before: 215522, No. 1, Fulin Road, fluorine chemical industry park, Changshu Economic Development Zone, Jiangsu, Suzhou Applicant before: Changshu Huayi Chemical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CHANGZHOU HUAYI CHEMICAL CO., LTD. TO: JIANGSU HUAYI ECHNOLOGY CO., LTD. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120725 |